Piramal Pharma · NSE: PPLPHARMA · BSE: 543635
Q3 FY23 results · Oct–Dec 2022
Piramal Pharma reported revenue from operations of ₹1,715.97 crore and net loss of ₹90.18 crore for Q3 FY23 (Oct–Dec 2022), on a consolidated basis.
| Item | Q3 FY23 | Q3 FY22 | YoY | Q2 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,715.97 | — | — | 1,720.01 | −0.2% |
| Other income | 82.54 | — | — | 46.22 | +78.6% |
| Total income | 1,798.51 | — | — | 1,766.23 | +1.8% |
| Profit before share of associates & JVs and tax | (89.21) | — | — | (37.35) | Loss widened |
| Share of profit/(loss) of associates & JVs | 15.57 | — | 11.09 | ||
| Net profit for the period | (90.18) | — | — | (37.34) | Loss widened |
| EPS, basic (₹) | (0.76) | — | — | (0.31) | not comparable |
| Net margin (%) | -5.3 | — | -2.2 |
This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.
| Item | Q3 FY23 | Q3 FY22 | YoY | Q2 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 813.29 | — | — | 828.87 | −1.9% |
| Other income | 53.88 | — | — | 117.70 | −54.2% |
| Total income | 867.17 | — | — | 946.57 | −8.4% |
| Profit before tax | 0.74 | — | — | 81.90 | −99.1% |
| Net profit for the period | (2.42) | — | — | 47.33 | Turned loss |
| EPS, basic (₹) | (0.02) | — | — | 0.40 | not comparable |
| Net margin (%) | -0.3 | — | 5.7 |
Consolidated
- Filed with BSE
- 10 Feb 2023, 15:53 IST
- Board meeting
- 08 Feb 2023
- Period
- 01 Oct 2022 to 31 Dec 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 10 Feb 2023, 15:53 IST
- Board meeting
- 08 Feb 2023
- Period
- 01 Oct 2022 to 31 Dec 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE